171 results about "Arterial Vasodilation" patented technology

The invention provides methods for inducing or increasing the vasodilation of a vessel. The invention further provides methods for inducing or increasing the flow of fluid through a vessel. An electrical impulse is applied to the vessel in order to induce or increase vessel vasodilation or to induce or increase the flow of fluid through the vessel. In a particular embodiment, a novel double-balloon catheter system incorporating electroporation technology has been designed and is used to apply the electrical impulse endoluminally.

A method for treating congestive heart failure (CHF) has been developed that restores kidney renal functions by artificial vasodilation of at least one kidney. A vasodilator drug is locally delivered to the kidney via a kidney perfusion catheter. The drug can be mixed with the patient's blood, saline or other suitable solvent and the mixture directly applied to the kidney through the catheter. The restoration of kidney function assists the heart by removing excess fluid, urine and toxin from the patient, and by normalizing the patient's renin-angiotensin system and other neurohormonal substances. The method is applicable to treat chronic and acute CHF.

This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula:

Methods, computer programming and devices for transferring heat to and / or from a body portion of a mammal are provided. One approach includes directly determining a state of vasoconstriction or vasodilation in a portion of a body, and supplying heat to the portion of the body when vasoconstriction is determined, and removing heat from the portion of the body when vasodilation is determined. The body portion preferably includes specific heat exchange vasculature. In another approach, a transition of the body portion from a state of vasodilation to vasoconstriction is determined and the body portion is then actively kept in a state of vasodilation while removing heat therefrom.

A method and apparatus for the prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), lower extremity edema, and other associated medical conditions by adjusting the temperature of the muscles of a foot or a leg, and / or applying vacuum or negative pressure to increase blood flow. A human extremity such as a leg is exposed to a negative pressure environment and / or a thermally controlled environment within a medical device. In one aspect, the device is portable. A thermal exchange unit and, optionally, a vacuum or negative pressure unit, are provided to increase blood flow and vasodilation. The device can be programmed by a controller in a manner to stimulate the muscles of the extremity to reduce pooling of blood therein.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing direct current electricity. Electrodes are used to deliver a direct current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, perdiodontitis, and oral malodor while also promoting general oral hygiene.

Topical gelled compositions comprising a drug which causes vasodilation, and optionally prostaglandin E1, dispersed within a polymer matrix, and methods of treating sexual dysfunction, including both male and female sexual dysfunction, using said compositions.

A warming system, mounted to the foot of a bed, warms a person's lower extremities by directing air into the space between the mattress and overlaying blankets. A blower directs air into an elongated distribution chamber having many tiny exit apertures. The chamber is mounted at the foot of the bed, so that air exiting the apertures warms the person's feet. For maximum thermal transfer, the chamber is placed under the sheet and any blankets, but above the mattress cover and fitted sheet. The chamber may be implemented by a length of open cell foam, a hollow manifold with many punctures or other tiny distribution apertures, collapsible pocket, etc. While the person is lying on the bed beneath the blankets, with feet proximate the foot of the bed, the blower directs temperature-regulated air into the chamber and through the exit apertures, thereby warming the person's feet. A temperature regulator ensures a normothermic air temperature (or alternatively, hyperthermic air temperature.) Thus, the invention helps relieve or prevent "cold feet" by directing normothermic air at a person's lower extremities. Additionally, by applying heat to the feet and legs, the invention encourages blood flow by virtue of sympathetic vasodilation and local temperature-mediated vasodilation. The invention is also believed to prevent some leg and foot ulcers from forming by maintaining the lower extremity at a near normal temperature during sleep.

The present invention discloses proteinaceous compounds that comprise at least a biologically active portion of a taipan natriuretic peptide (TNP) or a variant or derivative thereof. The invention also relates to the use of these compounds in methods for stimulating vasodilation, natriuresis, diuresis, renin-suppression, bactericidal activity, weight-loss or bone growth in a mammalian host. In specific embodiments, the compounds are useful in the treatment of congestive heart failure.

A method for increasing cerebral blood flow in a patient. A electrical stimulating device is provided. The electrical stimulating device is applied to the patient at a region adjacent the cervical sympathetic chain, the brain stem, the head, or the sympathetic nervous system. The electrical stimulating device is applied by any route selected from transcutaneous, subcutaneous, and subarachnoid. The electrical stimulating device is activated to stimulate or inhibit nerve impulses of the cervical sympathetic chain, thereby producing vasodilation in the cerebral vasculature, thereby increasing cerebral blood flow. Devices for increasing cerebral blood flow in a patient are also described.

The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.

A method and apparatus for the concurrent treatment of multiple oral diseases and defects while promoting general oral hygiene utilizing direct current electricity. Electrodes are used to deliver a direct current to the gingival tissues of a mouth in order to achieve a number of therapeutic, prophylactic, and regenerative benefits. These benefits include killing oral microbes, increasing oral vasodilation, reducing oral biofilm, improving oral blood circulation, reversing oral bone resorption, promoting oral osteogenesis, treating gum recession, and fostering gingival regeneration. Other benefits include the treatment of gingivitis, periodontitis, and oral malodor, and other systemic diseases correlated with oral pathogens.

An invention that adduces cogent evidence to establish that oxygenated dibenzo-α-pyrones (DBPs and their conjugates), the major bioactives of shilajit (Ayurvedic vitalizer), have their origin, at least partly, in EPA and DHA. Earlier research has shown that, in mammals, C-20 PUFAs are metabolized by oxygenases and other enzymes to produce short-lived prostaglandins, leukotrienes and thromboxanes that bind to specific G-protein-coupled receptors and signal cellular responses, e.g., inflammation, vasodilation, blood pressure, pain etc. But never before it was suggested / shown that C20:5n-3 (and C22:6 n-3) PUFAs, e.g., EPA (and DHA), are transformed into stable aromatic metabolites, DBPs, which elicit a large array of bioactivities in the producer organisms and also control the synthesis and metabolism of arachidonate-derived prostaglandins. The major beneficial effects attributed to EPA and DHA are now found to be largely contributed by DBPs and their aminoacyl conjugates and the dibenzo-α-pyrone-chromoproteins (DCPs). Because of the highly unstable nature of EPA and DHA, when administered, they are metabolized into a large array of uncontrolled products, several of which are systemically undesirable. By contrast, DBPs, because of their stability, perform the biological response modifier (BRM) functions in a directed and sustained way. Many of the biological effects of DBPs described in this invention, were earlier attributed to EPA and DHA,—the precursors of DBPs.

Active cooling of a person, such as to induce mild / moderate hypothermia, is accomplished by transferring heat from the persons body. Heat transfer and patient comfort are aided by administration of an anti-shivering drug and an anti-emetic drug.

The invention relates to a methods and devices of delivering gaseous nitric oxide to a mammal or surface at a concentration ranging from about 1000 ppm to about 50,000 ppm of gaseous nitric oxide. Different conditions which can be treated by high dosage administration of gNO include but are not limited to: topical treatments with gNO, cosmetic applications of gNO, vasodilation conditions with gNO, inhalation treatments with gNO, treatments of the blood with gNO, treatment of the skin or tissue with gNO, treatment of infections with gNO, treatment of inflammation on or within the body, and treatments of biofilms with gNO. Other conditions, aliments, or symptoms that may be treated with high dosage gNO include bronchoconstriction, reversible pulmonary vasoconstriction, asthma, pulmonary hypertension, adult respiratory distress syndrome (ARDS), and persistent pulmonary hypertension of the newborn (PPHN).

The present invention relates to novel compounds that are novel adenosine receptor analogues. Specifically, the compounds of the present invention preferably function as both adenosine receptor agonists and ganglionic blocking agents. To achieve this functionality, the compounds of the present invention, preferably contain a ganglionic blocking motif, is inserted into the adenosine molecule. The ganglionic blocking motif preferably includes an elongated carbon chain that, in a particularly preferred embodiment, contains two terminal amino groups. The ganglionic blocking motif preferably includes a carbon along the elongated carbon chain that is integral to a cyclic ketal that is part of the adenosine molecule. In presently-preferred embodiments, the elongated carbon chain ranges from two to sixteen carbons in length. The compounds of the present invention will be useful for treatment of a variety of conditions including, but not limited to, hypertension, vasodilation, and ischemia.

The invention generally relates to angiogenic factors and more particularly to the angiopoietin family of growth factors and to methods of using these growth factors to induce vasodilation and hypotension and reducing hypertension.

The present invention relates to methods for myocardial imaging by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof A2A adenosine receptor agonist to a human undergoing myocardial imaging. The invention also relates to methods of producing coronary vasodilation without significant peripheral vasodilation by administering at least one 2-adenosine N-pyrazole, 2-adenosine C-pyrazole or a combination thereof adenosine A2A adenosine receptor agonist to a human.

The present invention relates to the novel use of prostacyclin analogs for prevention and / or treatment of capillary leakage during surgery. The treatment of the present invention mediates discrete or minimal effects on haemostasis and vasodilation. Thus the present invention provides prostacyclin and analogs thereof for treatment which prevents capillary leakage while minimizing the risk of bleeding. The present invention further provides pharmaceutical compositions and kits of parts comprising prostacyclin or analogs thereof, and methods for treatment.

A method and apparatus for the prevention of deep vein thrombosis (DVT), pulmonary embolism (PE), lower extremity edema, and other associated medical conditions by adjusting the temperature of the muscles of a foot or a leg, and / or applying vacuum or negative pressure to increase blood flow. A human extremity such as a leg is exposed to a negative pressure environment and / or a thermally controlled environment within a medical device. In one aspect, the device is portable. A thermal exchange unit and, optionally, a vacuum or negative pressure unit, are provided to increase blood flow and vasodilation. The device can be programmed by a controller in a manner to stimulate the muscles of the extremity to reduce pooling of blood therein.